Bayer, Cardiol Therapeutics, Evotec - Is monkeypox providing new momentum in the biotech and pharma sector?

Bayer - New pharma products with good results

Bayer has recently made significant progress in its product development. Elinzanetant, a non-hormonal treatment for menopausal symptoms, has received a marketing authorization application from the FDA following positive results from Phase III studies. At the same time, finerenone has shown significant cardiovascular benefits for patients with heart failure in the Phase III study FINEARTS-HF. These developments underscore Bayer's commitment to bringing innovative and effective therapies to market that can significantly improve both healthcare and patient care.

In Q2 2024, Bayer achieved revenue of EUR 11.144 billion, an increase of 3.1% compared to the previous year. However, EBITDA before exceptionals decreased by 16.5% to EUR 2.111 billion. Fortunately, free cash flow increased to EUR 1.273 billion, compared with a negative figure of EUR -473 million in the previous year. In addition, Bayer reduced its net financial debt by 1.9% to EUR 36.760 billion. These mixed results reflect the Company's challenges and progress and highlight the need to continue both revenue growth and efficiency improvements.

For 2024, Bayer has confirmed its growth forecast, with revenues in Crop Science expected to vary between -1% and +3% and for Pharmaceuticals between 0% and +3%. For Consumer Health, the Company expects growth of between 3% and 6%. Despite the existing challenges, Bayer remains optimistic and is focusing on stable development. The focus remains on the launch of new products such as elinzanetant and finerenone, which could be key drivers for future growth. On the other hand, the legal disputes must be settled in order to enter calmer waters. The share is currently trading at EUR 28.37.

Cardiol Therapeutics - Positive Phase II results

Cardiol Therapeutics is a clinical-stage company focused on the research and development of anti-inflammatory and anti-fibrotic therapies in the treatment of heart disease. The Company's lead product, CardiolRx™, an orally administered formulation, aims to effectively inhibit inflammatory processes that can lead to rare diseases such as myocarditis and pericarditis. Cardiol has received clinical trial approval from the US Food and Drug Administration (FDA) to evaluate the efficacy and safety of CardiolRx™ in a Phase II pilot study specifically targeting the treatment of recurrent pericarditis and another Phase II study aimed at combating myocarditis.

The ongoing MAvERIC-Pilot study is investigating the effect of CardiolRx™ in 27 patients with symptomatic recurrent pericarditis. Initial results showed a significant reduction in pain reported by patients within eight weeks and normalization of inflammatory markers in 80% of participants with elevated CRP. In the study, the drug was considered safe and 89% of participants prolonged treatment. These results suggest that treatment with CardiolRx™ offers comparable outcomes to established biologic therapies, strengthening the prospect of entry into the Phase III study. Phase III is anticipated to provide a broader, non-immunosuppressive treatment option for patients.

Based on the positive study results, the market is optimistic that the shares have further potential. The analysts recommend the share as a "Buy" with an average price target of CAD 9.75, which is roughly equivalent to USD 7.15. The share price has risen by almost 280% at its peak this year and has since consolidated. At a share price of USD 1.95 on the NASDAQ, the gain is still 130% since the beginning of the year.

Evotec - Quarterly figures after the profit warning

The Hamburg-based drug discovery company Evotec surprised the market at the beginning of August with a significant reduction in its profit forecast. The Company now expects EBITDA of between EUR 15 and 35 million for the financial year 2024. This represents a considerable decrease compared to the previous year when adjusted EBITDA amounted to EUR 66.4 million. Evotec is facing delayed order intake and continued high-cost pressure. The announcement led to a significant drop in the share price, which has recently recovered slightly.

Amidst the negative news, there were also positive developments: The strategic partnership with Bristol Myers Squibb is showing progress. Evotec received a payment of USD 25 million for further research in the field of neurodegeneration. The collaboration, initiated in 2016, aims to develop novel treatments for neurodegenerative diseases. This partnership adds significantly to Evotec's scientific and commercial potential by generating promising pipeline projects that have progressed to the clinical stage.

The quarterly results on August 14 reflect the challenges facing the Company. Although revenue rose by 7% to EUR 182.1 million, the loss in Q2 amounted to almost EUR 95 million, around six times higher than in the same period last year. The slow conversion of orders into sales and the high proportion of fixed costs had a noticeable negative impact on earnings. Despite these setbacks, the management emphasizes the progress made in the realignment towards profitable growth. It expects long-term positive effects from the measures introduced to reduce costs and increase efficiency. The share is currently available for EUR 5.75.

The outbreak of monkeypox has once again highlighted the importance of the biotech and pharmaceutical industry. Bayer has made significant progress with new drugs such as elinzanetant and finerenon despite mixed results. Cardiol Therapeutics impresses with positive Phase II data for CardiolRx™, which bodes well for future developments. Evotec is facing lowered profit forecasts but continues to make advances in its partnership with Bristol Myers Squibb. Overall, it is clear that innovative developments and strategic partnerships are key to advancing the healthcare sector and overcoming future challenges.